No Detail Found!

Mavorixafor: a spotlight on the clinical aspects and prospects of the first USFDA-approved treatment for the primary immunodeficiency WHIM syndrome

Author(s)
Mohd Imran Department of Pharmaceutical Chemistry, College of Pharmacy,Northern Border University, Rafha, Saudi Arabia. ; Center for Health Research,Northern Border University, Arar ,Saudi Arabia
Abdulaziz Khalaf Alshammari College of Pharmacy, Northern Border University, Kingdom of Saudi Arabia, Hafar Al-Batin , Saudi Arabia
Khalid Ramadan Alhamad Almoosa Health, Al-Ahsa , Saudi Arabia
Majd Ahmed Alghamdi Al-Dawaa Medical Services Company, Dammam , Saudi Arabia
Maryam Adnan Alghareeb College of Clinical Pharmacy, King Faisal University, Al-Ahsa, Saudi Arabia
Renad Adnan Alghareeb College of Clinical Pharmacy, King Faisal University, Al-Ahsa, Saudi Arabia
Omar Ibrahim Aldhafiri Al-Dawaa Medical Services Company, Hafar Albatin , Saudi Arabia
Jumanah Basem Al-Humud College of Pharmacy, Mohammed AL-Mana College forMedical Science, Dammam ,Saudi Arabia
Syed Mohammed Basheeruddin Asdaq Department of Pharmacy Practice, College of Pharmacy,AlMaarefa University, Dariyah,, Riyadh , Saudi Arabia
Abida Department of Pharmaceutical Chemistry, College of Pharmacy,Northern Border University, Rafha , Saudi Arabia
Abstract
WHIM syndrome (WHIMS) is an extremely rare, severe, and potentially fatal genetic condition that affects the immune system, leading to warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM). Effective therapy for WHIMS requires regular monitoring, medical intervention, and a collaborative approach to treatment. Due to the limited therapeutic options, addressing WHIMS is an unmet medical need. The United States Food and Drug Administration (USFDA) recently granted approval for mavorixafor as the first treatment for WHIMS. This review focuses on the pharmacological characteristics, clinical investigations, associated inventions, and prospects of mavorixafor. The literature for this article was searched on PubMed, reputable websites (USFDA and X4 Pharmaceuticals) and free patent databases like Espacenet. WHIMS is distinguished by severe neutropenia and hypogammaglobulinemia, which increases the risk of developing cancer. Mavorixafor enhances the movement of neutrophils and lymphocytes from the bone marrow (BM) to the bloodstream. Hence, it could be beneficial for managing medical illnesses characterized by a decrease in the quantity of neutrophils and lymphocytes in the bloodstream. X4 Pharmaceuticals has submitted patent applications for the utilization of mavorixafor in the treatment of diverse cancer types, inflammatory ailments, B-cell dysfunction, Waldenstrom's macroglobulinemia, and primary immunodeficiency disorders. This suggests that mavorixafor can effectively treat various disorders either alone or when used in conjunction with other medications. It will be intriguing to observe the future approvals of mavorixafor for various disorders.
Publication Details
Page(s) 726-732
DOI DOI not available
Published Journal: Advancements in life sciences, Volume: 11, Issue: 4, Year: 2024

Request the full text from PASTIC

Keywords
cancer, Immunodeficiency, Prospect, Patent, Mavorixafor, WHIM syndrome
References
Heusinkveld LE,Majumdar S,Gao JL,McDermott DH,Murphy PM .2019 .WHIM Syndrome: from pathogenesis towards personalized medicine and cure. Journal of Clinical Immunology, 39(6) : 532-556.
Immunological reviews .2019 .. , 287(1) : 91-102.
Majumdar S,Murphy PM .2018 .Adaptive immunodeficiency in WHIM syndrome. International Journal of Molecular Sciences, 20(1) : 3.
Janssens R,Struyf S,Proost P .2018 .Pathological roles of the homeostatic chemokine CXCL12. Cytokine Growth Factor Reviews, 44 : 51-68.
Rodríguez-Frade JM,González-Granado LI,Santiago CA,Mellado M. .2024 .The complex nature of CXCR4 mutations in WHIM syndrome. , 15 : 1406532.
.2024 .Expanding CXCR4 variant landscape in WHIM syndrome: integrating clinical and functional data for variant interpretation. , 15 : 1411141.
Part C .2022 .. , 190(2) : 215-221.
SM. Mavorixafor Hoy .2024 .. , 84(8) : 969-975.
Blood .2024 .. , 144(1) : 1-2.
Book Orange .2024 .Approved Drug Products with Therapeutic Equivalence Evaluations. cfm (Accessed on June 30, : .
.2024 .Center For Drug Evaluation and Research. Product Quality Review(s). pdf (Accessed on June 30, : .
.2024 .. pdf (Accessed on June 30, : .
.2024 .. Accessed on July 25, : .
.2024 .Center For Drug Evaluation and Research. Risk Assessment and Risk Mitigation Review(s). pdf (Accessed on June 30, : .
.2024 .Center For Drug Evaluation and Research. Integrated review. pdf (Accessed on June 30, : .
.2024 .Center For Drug Evaluation and Research. pdf (Accessed on June 30, : .
Andtbacka RHI,Wang Y,Pierce RH,Campbell JS,Yushak M .2022 .Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma. Cancer Research Communications, 2(8) : 904-913.
Choueiri TK,Atkins MB,Rose TL,Alter RS,Ju Y . .A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy.. , : .
New Investigational,Drugs Investigational .2021 .. , 39(4) : 1019-1027.
.2020 .Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome. Blood, 136(26) : 2994-3003.
.2024 .A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome. Blood, 144(1) : 35-45.
.2020 .Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome. Blood, 136(26) : 2994-3003.
.2012 .The molecular pharmacology of AMD11070: an orally bioavailable CXCR4 HIV entry inhibitor. Biochemical pharmacology, 83(4) : 472-479.
Hudu SA,Elmigdadi F,Qtaitat AA,Almehmadi M,Alsaiari AA .2023 .Trofinetide for Rett Syndrome: Highlights on the Development and Related Inventions of the First USFDAApproved Treatment for Rare Pediatric Unmet Medical Need. Journal of Clinical Medicine, 12(15) : 5114.
Hudu SA,Alshrari AS,Al Qtaitat A,Imran M. . .VP37 protein inhibitors for Mpox treatment: Highlights on recent advances, patent literature, and future directions. , : .
Biomedicines .2023 .. , 11(4) : 1106.
Biomedicines .2023 .. , 11(2) : 426.
KMJ Brands .2020 .Compositions of CXCR4 inhibitors and methods of preparation and use. United States Patent Number US10548889B1, : .
Arbeit RD,Ragan PM .2020 .Methods for treating immunodeficiency disease. United States Patent Number US10610527B2, : .
Ragan PM,Arbeit RD,Crowley KJ .2021 .Methods for treating cancer. United States Patent Number US10953003B2, : .
KM Brands .2021 .Compositions of CXCR4 inhibitors and methods of preparation and use. United States Patent Number US11045461B2, : .
Arbeit RD,Ragan PM .2022 .Methods for treating immunodeficiency disease. United States Patent Number US11219621B2, : .
.2022 .Methods for treating cancer. United States Patent Number US11357742B2, : .
Johnson VA,Cramer YS,Rosenkranz SL,Becker S,Klingman KL . .Antiretroviral Activity of AMD11070 (An Orally Administered CXCR4 Entry Inhibitor): Results of NIH/NIAID AIDS Clinical Trials Group Protocol A5210. , : .
.2019 .. AIDS Research and Human Retroviruses, 35(8) : 691-697.
Tripathi R .2023 .Preliminary study to identify CXCR4 inhibitors as potential therapeutic agents for Alzheimer's and Parkinson's diseases. Integrative Biology (Camb), 15 : zyad012.
Miao M,De Clercq E,Li G. .2020 .Clinical significance of chemokine receptor antagonists. Expert Opinion on Drug Metabolism & Toxicology, 16(1) : 11-30.
Uchida D,Kuribayashi N,Kinouchi M,Sawatani Y,Shimura M .2018 .Effect of a novel orally bioavailable CXCR4 inhibitor, AMD070, on the metastasis of oral cancer cells. Oncology Reports, 40(1) : 303-308.
Hanselmann R,Brands KMJ .2023 .Synthesis of mavorixafor and intermediates thereof. WO2023059903A1, : .
Hines D,Hines R .2023 .Methods of treating 5HT2a receptormediated conditions. WO2023212244A1, : .
Arkin I,Singh TPP,Krugliak M. .2023 .E protein channel blockers and orf3 inhibitors as anti-covid-19 agents. US2023190769A1, : .
Zhang Y,Liu D,He H,Ma M,Wang J .2024 .Double-targeting tumor microenvironment response multifunctional nano delivery system and preparation method and application thereof. Chinese Patent Number CN115252790B, : .
Imran M,Khan SA,Alshrari AS,Eltahir Mudawi MM .2022 .Small molecules as kinetoplastid specific proteasome inhibitors for leishmaniasis: a patent review from 1998 to 2021. , 32(5) : 591-604.
Imran M,Khan SA,Alshammari MK,Alqahtani AM,Alanazi TA .2022 .Discovery, Development, Inventions and Patent Review of Fexinidazole: The First All-Oral Therapy for Human African Trypanosomiasis. Pharmaceuticals (Basel), 15(2) : 128.
Imran M,Alshrari AS,Thabet HK .2021 .Synthetic molecules as DprE1 inhibitors: A patent review. Expert Opinion on Therapeutic Patents, 31(8) : 759-772.
Nyunt MM,Becker S,MacFarland RT,Chee P,Scarborough R .2008 .Pharmacokinetic effect of AMD070, an Oral CXCR4 antagonist, on CYP3A4 and CYP2D6 substrates midazolam and dextromethorphan in healthy volunteers. Journal of Acquired Immune Deficiency Syndromes, 47(5) : 559-565.
Cao YJ,Flexner CW,Dunaway S,Park JG,Klingman K .2008 .Effect of low-dose ritonavir on the pharmacokinetics of the CXCR4 antagonist AMD070 in healthy volunteers. Antimicrobial Agents and Chemotherapy, 52(5) : 1630-1634.
. .To read the copy of this license please visit: https://creativecommons. , : .
0

Citations

0

Downloads

57

Views